BTIG Research Increases Personalis (NASDAQ:PSNL) Price Target to $13.00

Personalis (NASDAQ:PSNL) had its price target hoisted by stock analysts at BTIG Research from $12.00 to $13.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 54.95% from the stock’s current price.

Several other brokerages have also recently commented on PSNL. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Guggenheim boosted their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Morgan Stanley upped their price target on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Finally, HC Wainwright increased their price target on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Personalis currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.86.

Personalis Trading Down 5.7%

PSNL stock opened at $8.39 on Wednesday. The business’s fifty day moving average price is $8.88 and its 200 day moving average price is $7.70. Personalis has a 12-month low of $2.83 and a 12-month high of $11.50. The company has a market capitalization of $745.03 million, a PE ratio of -9.53 and a beta of 1.98.

Insider Buying and Selling

In other news, CFO Aaron Tachibana sold 103,668 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the completion of the sale, the chief financial officer owned 164,458 shares in the company, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Personalis

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in shares of Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after purchasing an additional 33,044 shares during the period. Goldman Sachs Group Inc. grew its stake in Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after buying an additional 101,706 shares during the last quarter. Focus Partners Wealth acquired a new position in Personalis during the first quarter worth approximately $47,000. Finally, Aberdeen Group plc increased its position in Personalis by 3.2% during the second quarter. Aberdeen Group plc now owns 1,759,497 shares of the company’s stock worth $11,542,000 after buying an additional 54,713 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.